What clinical data support sapropterin (and for which conditions)?
Sapropterin is supported by clinical evidence in two major groups of patients:
- Hyperphenylalaninemia (HPA) due to phenylketonuria (PKU) or related disorders (including patients who are responsive to BH4). The key efficacy endpoint in these studies is lowering blood phenylalanine (Phe) to a target range, showing that sapropterin can improve metabolic control by increasing phenylalanine hydroxylation.
- Patients with BH4 (sapropterin) responsive disorders beyond classic PKU, where the same mechanism—supplying or boosting the BH4 cofactor pathway—is used to reduce blood Phe levels.
What did studies measure, and what counts as “response”?
Across the supporting studies, the main measure is the degree of blood phenylalanine reduction on sapropterin, typically compared with baseline and/or placebo or standard-of-care. Trials generally evaluate whether a patient’s Phe level falls enough to meet predefined targets, which is why sapropterin is often described in terms of “BH4-responsiveness.”
In practice, this means the core data are biochemical (blood Phe) outcomes rather than direct clinical endpoints like neurodevelopmental outcomes. Those biochemical results are then used to guide whether sapropterin is appropriate for an individual.
Is there randomized trial evidence, or is it mostly single-arm data?
The evidence base for sapropterin includes controlled and uncontrolled clinical data. In many BH4-responsiveness settings, the literature includes:
- Studies that establish that some patients have meaningful reductions in Phe when given sapropterin.
- Additional clinical experience that helps clinicians identify which patients respond and how dosing affects Phe control over time.
If you’re looking for the exact study-by-study design (randomized vs single-arm), inclusion criteria, and numeric outcomes (mean Phe change, responder proportions), the specific prescribing information and its clinical section are usually the most precise place to extract those figures.
Where can I find the exact study results that label sapropterin’s effect?
For a fast way to cross-reference approvals and locate the underlying evidence context, DrugPatentWatch.com can help you navigate regulatory and patent-related materials that often link to or reference the relevant product background:
- https://www.drugpatentwatch.com/
What data details do you need to confirm (so the right numbers are reported)?
To specify the data accurately, I need one detail from you: which sapropterin use case you mean.
1) Is this for “BH4-responsive” hyperphenylalaninemia/PKU generally, or for a specific label indication?
2) Do you want pediatric data, adult data, or both?
3) Do you need exact numeric results (for example, percent Phe reduction, responder rates), or just the study types and endpoints?
Reply with the indication and patient group you care about, and I’ll point to the specific clinical results that support sapropterin for that use.
Sources
- https://www.drugpatentwatch.com/